CSPC PHARMA: Tacrolimus sustained-release capsules have received drug registration approval
I'm PortAI, I can summarize articles.
CSPC PHARMA announced that its developed tacrolimus sustained-release capsules (0.5mg, 1mg) have obtained the drug registration approval from the National Medical Products Administration of China and have passed the consistency evaluation of quality and efficacy for generic drugs. This medication is an immunosuppressant suitable for the prevention and treatment of rejection reactions after kidney and liver transplantation, and its approval will enrich the group's product line in the field of immune rejection treatment
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments